BR112014015442A8 - compostos e composições para inibir a interação de bcl2 com parceiros de ligação - Google Patents
compostos e composições para inibir a interação de bcl2 com parceiros de ligaçãoInfo
- Publication number
- BR112014015442A8 BR112014015442A8 BR112014015442A BR112014015442A BR112014015442A8 BR 112014015442 A8 BR112014015442 A8 BR 112014015442A8 BR 112014015442 A BR112014015442 A BR 112014015442A BR 112014015442 A BR112014015442 A BR 112014015442A BR 112014015442 A8 BR112014015442 A8 BR 112014015442A8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- bcl
- interaction
- compositions
- binding partners
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 13
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title abstract 9
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title abstract 8
- 230000003993 interaction Effects 0.000 title abstract 7
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101150017888 Bcl2 gene Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
compounds and compositions for inhibiting the interaction of bcl2 with binding partners abstract the present invention relates to compounds of formula i: in which r1, r2, r3 and r4 are as defined in the summary of the invention. compounds of formula i are capable of disrupting the bcl-2 interations with proteins containing a bh3 domain. disrupting this interaction can restore the anti-apoptotic function of bcl-2 in cancer cells and tumor tissue expressing bcl-2. the invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancerous diseases. tradução do resumo resumo "compostos e composições para inibir a interação de bcl2 com parceiros de ligação" a presente invenção refere-se a compostos de fórmula i: em que r1, r2, r3 e r4 são como definidos no sumário da invenção. os compostos de fórmula i são capazes de perturbar as interações bcl-2 com proteínas contendo um domínio bh3. perturbar esta interação pode restaurar a função antiapoptótica de bcl-2 em células cancerosas e tecido tumoral que expressa bcl-2. a invenção proporciona ainda um processo para a preparação de compostos da invenção, preparações farmacêuticas que compreendem estes compostos e métodos de utilização de tais compostos no tratamento de doenças cancerosas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579740P | 2011-12-23 | 2011-12-23 | |
PCT/US2012/069191 WO2013096051A1 (en) | 2011-12-23 | 2012-12-12 | Compounds for inhibiting the interaction of bcl2 with binding partners |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014015442A2 BR112014015442A2 (pt) | 2017-06-13 |
BR112014015442A8 true BR112014015442A8 (pt) | 2017-07-04 |
Family
ID=47429050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014015442A BR112014015442A8 (pt) | 2011-12-23 | 2012-12-12 | compostos e composições para inibir a interação de bcl2 com parceiros de ligação |
Country Status (11)
Country | Link |
---|---|
US (1) | US20140350014A1 (pt) |
EP (1) | EP2794589A1 (pt) |
JP (1) | JP2015503516A (pt) |
KR (1) | KR20140107578A (pt) |
CN (1) | CN104136428A (pt) |
AU (1) | AU2012355615A1 (pt) |
BR (1) | BR112014015442A8 (pt) |
CA (1) | CA2859873A1 (pt) |
EA (1) | EA201491259A1 (pt) |
MX (1) | MX2014007725A (pt) |
WO (1) | WO2013096051A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104125954A (zh) | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
US9126980B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
FR3008976A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
FR3008978A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
FR3008979B1 (fr) | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
EP3788042A4 (en) | 2018-04-29 | 2022-01-26 | BeiGene, Ltd. | BCL-2 INHIBITORS |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (pt) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
JP4146514B2 (ja) | 1995-07-06 | 2008-09-10 | ノバルティス アクチエンゲゼルシャフト | ピロロピリミジン類およびその製造方法 |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
SI0892789T2 (sl) | 1996-04-12 | 2010-03-31 | Warner Lambert Co | Ireverzibilni inhibitorji tirozin kinaz |
CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
WO1998010121A1 (en) | 1996-09-06 | 1998-03-12 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
AU4342997A (en) | 1996-09-13 | 1998-04-02 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
PT941227E (pt) | 1996-11-18 | 2004-08-31 | Biotechnolog Forschung Mbh Gbf | Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2002504540A (ja) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | エポチロンの合成、その中間体およびそのアナログ |
JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
AU768220B2 (en) | 1998-11-20 | 2003-12-04 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
JP4731016B2 (ja) | 1998-12-22 | 2011-07-20 | ジェネンテック, インコーポレイテッド | 血管内皮細胞増殖因子アンタゴニストとその用途 |
ES2265929T3 (es) | 1999-03-30 | 2007-03-01 | Novartis Ag | Derivados de ftalazina para el tratamiento de enfermedades inflamatorias. |
US6703382B2 (en) | 2000-08-16 | 2004-03-09 | Georgetown University Medical Center | Small molecule inhibitors targeted at Bcl-2 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
NZ529792A (en) | 2001-05-30 | 2007-04-27 | Univ Michigan | Small molecule antagonists of Bcl-2 family proteins |
US20030119894A1 (en) | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
EP1778206A4 (en) * | 2004-08-20 | 2009-08-05 | Univ Michigan | SMALL MOLECULAR INHIBITORS OF BCL-2 ANTI-APOPTOSIS FAMILY MEMBERS AND CORRESPONDING USES THEREOF |
CN103732589B (zh) * | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺 |
-
2012
- 2012-12-12 JP JP2014549135A patent/JP2015503516A/ja active Pending
- 2012-12-12 US US14/366,860 patent/US20140350014A1/en not_active Abandoned
- 2012-12-12 AU AU2012355615A patent/AU2012355615A1/en not_active Abandoned
- 2012-12-12 BR BR112014015442A patent/BR112014015442A8/pt not_active Application Discontinuation
- 2012-12-12 EP EP12805894.8A patent/EP2794589A1/en not_active Withdrawn
- 2012-12-12 EA EA201491259A patent/EA201491259A1/ru unknown
- 2012-12-12 CN CN201280070470.4A patent/CN104136428A/zh active Pending
- 2012-12-12 MX MX2014007725A patent/MX2014007725A/es unknown
- 2012-12-12 WO PCT/US2012/069191 patent/WO2013096051A1/en active Application Filing
- 2012-12-12 CA CA2859873A patent/CA2859873A1/en not_active Abandoned
- 2012-12-12 KR KR1020147020534A patent/KR20140107578A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2013096051A1 (en) | 2013-06-27 |
BR112014015442A2 (pt) | 2017-06-13 |
EA201491259A1 (ru) | 2014-11-28 |
US20140350014A1 (en) | 2014-11-27 |
KR20140107578A (ko) | 2014-09-04 |
CA2859873A1 (en) | 2013-06-27 |
JP2015503516A (ja) | 2015-02-02 |
EP2794589A1 (en) | 2014-10-29 |
CN104136428A (zh) | 2014-11-05 |
MX2014007725A (es) | 2015-01-12 |
AU2012355615A1 (en) | 2014-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014015339A2 (pt) | compostos para inibição da interação de bcl2 com parceiros de ligação | |
BR112014015442A2 (pt) | compostos e composições para inibir a interação de bcl2 com parceiros de ligação | |
BR112014015308A2 (pt) | compostos para inibição da interação de bcl2 com contrapartes de ligação | |
BR112014015322A2 (pt) | compostos e composições para inibir a interação de bcl2 com parceiros de ligação | |
BR112014015274A8 (pt) | compostos e composições para inibição da interação de bcl2 com parceiros de ligação | |
BR112012012918A8 (pt) | Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes | |
BR112015002152A2 (pt) | pirróis substituídos ativos como inibidores de quinases | |
BRPI0919447B8 (pt) | compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer | |
BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
BR112014007622A2 (pt) | inibidores de flt3 cinase macrocíclicos | |
EA201500394A1 (ru) | Ингибиторы деметилаз гистонов | |
BR112012004696B8 (pt) | composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação | |
BR112015011158A2 (pt) | triazolopirazina | |
BRPI1006115A8 (pt) | "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes". | |
NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
BR112016000975A8 (pt) | esteróides neuroativos, composições os compreendendo e uso dos mesmos | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
BR112015014458A8 (pt) | compostos derivados de manose, seus intermediários, composição, uso e processos de preparação | |
BR112012031727A2 (pt) | conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença. | |
BR112012029923A2 (pt) | agentes que induzem apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
CL2013001459A1 (es) | Compuestos derivados de quinazolincarboxamida azetidina; proceso para prepararlos; composicion farmaceutica que los comprende; set (kit); y su uso para el tratamiento de enfermedades hiperproliferativas tales como cancer, inflamacion, pancreatitis o enfermedad renal, dolor, hiperplasia benigna de piel entre otras. | |
BRPI0906444B8 (pt) | compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |